PMID- 31191023
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1179-1322 (Print)
IS  - 1179-1322 (Electronic)
IS  - 1179-1322 (Linking)
VI  - 11
DP  - 2019
TI  - Efficacy and safety of programmed death 1 inhibitors in patients with advanced 
      non-small cell lung cancer: a meta-analysis.
PG  - 4619-4630
LID - 10.2147/CMAR.S193394 [doi]
AB  - Objective: This study aims to perform systematic review and meta-analysis of all 
      randomized controlled trials that compare the efficacy and safety of programmed 
      death 1 (PD-1) inhibitors versus chemotherapy alone in previously untreated 
      advanced non-small cell lung cancer (NSCLC). Materials and methods: Several 
      databases, including Medline, Cochrane Library, Embase, and Web of Science, were 
      searched. The main outcome measures included overall survival (OS), 
      progression-free survival (PFS), objective response rate (ORR), and adverse 
      events (AEs). Results: The results of meta-analysis are expressed as the hazard 
      ratio (HR) or risk ratio (RR) with their corresponding 95% confidence intervals 
      (CIs). The final analysis included six trials for 3,930 patients. PD-1 inhibitors 
      led to a statistically superior survival benefit over chemotherapy in patients 
      with advanced NSCLC. OS was longer in patients who received PD-1 inhibitors (HR 
      =0.71, 95% CI =0.62-0.74, P=0.000). Furthermore, PD-1 inhibitors had 
      significantly higher objective response rate than chemotherapy (RR =0.20，95% CI 
      =0.17-0.23, P=0.000). Meta-analysis showed that the AEs of any grade with PD-1 
      inhibitors were lower than those with chemotherapy (RR =0.78; 95% CI =0.75-0.81, 
      P=0.000). Conclusion: PD-1 inhibitors showed a clinically meaningful survival 
      benefit and an improved safety profile in patients with previously treated NSCLC.
FAU - Liu, Yi
AU  - Liu Y
AD  - Department of Respiratory and Critical Care Medicine, The First Affiliated 
      Hospital of Anhui Medical University, Hefei, 230022, People's Republic of China.
FAU - Zhou, Sijing
AU  - Zhou S
AD  - Hefei Prevention and Treatment Center for Occupational Diseases, Hefei 230022, 
      People's Republic of China.
FAU - Du, Yongsheng
AU  - Du Y
AD  - Department of General Medicine, Hefei Second People's Hospital, Hefei 230022, 
      People's Republic of China.
FAU - Sun, Li
AU  - Sun L
AD  - Department of Respiratory and Critical Care Medicine, The First Affiliated 
      Hospital of Anhui Medical University, Hefei, 230022, People's Republic of China.
FAU - Jiang, Huihui
AU  - Jiang H
AD  - Department of Respiratory and Critical Care Medicine, The First Affiliated 
      Hospital of Anhui Medical University, Hefei, 230022, People's Republic of China.
FAU - Zhang, Binbin
AU  - Zhang B
AD  - Department of Respiratory and Critical Care Medicine, The First Affiliated 
      Hospital of Anhui Medical University, Hefei, 230022, People's Republic of China.
FAU - Sun, Gengyun
AU  - Sun G
AD  - Department of Respiratory and Critical Care Medicine, The First Affiliated 
      Hospital of Anhui Medical University, Hefei, 230022, People's Republic of China.
FAU - Wang, Ran
AU  - Wang R
AD  - Department of Respiratory and Critical Care Medicine, The First Affiliated 
      Hospital of Anhui Medical University, Hefei, 230022, People's Republic of China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190521
PL  - New Zealand
TA  - Cancer Manag Res
JT  - Cancer management and research
JID - 101512700
PMC - PMC6535411
OTO - NOTNLM
OT  - efficacy
OT  - lung cancer
OT  - programmed death 1
OT  - safety
COIS- The authors report no conflicts of interest in this work.
EDAT- 2019/06/14 06:00
MHDA- 2019/06/14 06:01
PMCR- 2019/05/21
CRDT- 2019/06/14 06:00
PHST- 2018/11/04 00:00 [received]
PHST- 2019/04/11 00:00 [accepted]
PHST- 2019/06/14 06:00 [entrez]
PHST- 2019/06/14 06:00 [pubmed]
PHST- 2019/06/14 06:01 [medline]
PHST- 2019/05/21 00:00 [pmc-release]
AID - 193394 [pii]
AID - 10.2147/CMAR.S193394 [doi]
PST - epublish
SO  - Cancer Manag Res. 2019 May 21;11:4619-4630. doi: 10.2147/CMAR.S193394. 
      eCollection 2019.